Stock Analiz

Coherus Oncology, Inc. CHRS

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2014 · data as of November 13, 2026

$0.53Market cap $81M
Open the interactive analysis →

Coherus Oncology, Inc. (CHRS) is a healthcare company listed in the US with a market value of about $81M. In the twelve months to September 30, 2026 it had revenue of $54M and net income of -$136M, a net margin of -253.4%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -264%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 86% below the current price.

About Coherus Oncology

Coherus Oncology is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2014. Revenue went from $31M in 2014 to $26M in 2024, a decline of about 1.6% a year. It was profitable in 4 of the last 10 years in our data. Its share count rose by 51% over three years (dilution for shareholders).

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.5
P/B3.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-749.7%
Shareholder yield0.0%
Intrinsic value vs. price−86%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)-2.5%
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-52.6%
ROIC (5-yr avg.)-263.9%
Profitable years (of last 10)4
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$54M—$26M$257M$211M$327M$476M$356M$0$2M$190M
Net income-$136M$168M$29M-$238M-$292M-$287M$132M$90M-$209M-$238M-$127M
Free cash flow—-$609M-$248M-$175M-$243M-$39M$147M$27M-$160M-$205M-$259M
EPS (diluted)$-1.00$1.43$0.25$-2.53$-3.76$-3.81$1.62$1.23$-3.22$-4.48$-2.96
Net margin-253.4%—108.0%-92.5%-138.2%-87.9%27.8%25.2%—-15306.6%-67.0%
ROIC—-281.7%———-246.1%52.1%88.7%—-760.2%-446.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Coherus Oncology stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 86% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Coherus Oncology pay a dividend?

Not currently.

Is Coherus Oncology a good stock to buy?

We do not give buy or sell advice. Coherus Oncology scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.